This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Takeda Pharmaceutical Company Ltd

Drug Names(s): VONOSAP Pack 400, VONOSAP Pack 800, VONOSAP (Takecab + Amolin + Clarith) [JP]

Description: VONOSAP is a triple-drug blister pack combining the acid suppressant TAKECAB tablet (generic name, vonoprazan fumarate) developed by Takeda, Amolin capsule (generic name, amoxicillin) and Clarith tablet (generic name, clarithromycin).

Deal Structure: Takeda and Otsuka
In March 2014, Otsuka and Takeda announced that the two firms have entered into a co-promotion agreement in Japan for TAK-438 (generic name: Vonoprazan Fumarate) for the treatment of acid-related diseases. The details of this agreement are as follows:

  • Otsuka will pay Takeda an up-front payment of 20 billion yen and a milestone payment upon NDA approval.
  • Otsuka will receive from Takeda a percentage of the sales (based on conditions specified in the contract).
  • Japan will be the area of promotion.
  • Further details will not be disclosed.

Partners: Otsuka Holdings Co., Ltd.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug